Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2

Abstract

VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in various cancer cells. Thus, VEGFER-2 inhibition is an efficient approach for the discovery of new anticancer agents. Accordingly, a new set of nicotinamide derivatives were designed and synthesized to be VEGFR-2 inhibitors. The chemical structures were confirmed using IR, 1H-NMR, and 13C-NMR spectroscopy. The obtained compounds were examined for their anti-proliferative activities against the human cancer cell lines (HCT-116 and HepG2). VEGFR-2 inhibitory activities were determined for the titled compounds. Compound 8 exhibited the strongest anti-proliferative activities with IC50 values of 5.4 and 7.1 µM against HCT-116 and HepG2, respectively. Interestingly, compound 8 was the most potent VEGFR-2 inhibitor with an IC50 value of 77.02 nM (compare to sorafenib: IC50 = 53.65 nM). Treatment of HCT-116 cells with compound 8 produced arrest of the cell cycle at the G0–G1 phase and a total apoptosis increase from 3.05 to 19.82%—6.5-fold in comparison to the negative control. In addition, compound 8 caused significant increases in the expression levels of caspase-8 (9.4-fold) and Bax (9.2-fold), and a significant decrease in the Bcl-2 expression level (3-fold). The effects of compound 8 on the levels of the immunomodulatory proteins (TNF-α and IL-6) were examined. There was a marked decrease in the level of TNF-α (92.37%) compared to the control (82.47%) and a non-significant reduction in the level of IL-6. In silico docking, molecular dynamics simulations, and MM-PBSA studies revealed the high affinity, the correct binding, and the optimum dynamics of compound 8 inside the active site of VEGFR-2. Finally, in silico ADMET and toxicity studies indicated acceptable values of drug-likeness. In conclusion, compound 8 has emerged as a promising anti-proliferative agent targeting VEGFR-2 with significant apoptotic and immunomodulatory effects.

Discovery of Anti‐Breast Cancer Thiophene Sulfonamide Derivatives: Design, Synthesis, Molecular Docking against EGFR, MM‐PBSA, MD Simulations, ADME/Tox, and in vitro Studies

“…The newly produced substances were tested for their cytotoxic activity [38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] using the cancer cell line (MCF-7) where Tamoxifen and Brigatinib are used as a cytotoxic reference drug. For this study cancer cells were exposed to the substances for 72 hours.…”

Design, Synthesis, and Biological Evaluation Studies of Novel Naphthalene-Chalcone Hybrids As Antimicrobial, Anticandidal, Anticancer, and VEGFR-2 Inhibitors

“…Several protein kinases, including the growth factors, regulate the angiogenesis process. The vascular endothelial growth factor (VEGF) is one of the most potent angiogenic determinants that can control angiogenesis and be involved in the development of a tumor among those growth factors . By interacting with VEGF receptor types 1–3, the VEGF family controls angiogenesis .…”

“…The vascular endothelial growth factor (VEGF) is one of the most potent angiogenic determinants that can control angiogenesis and be involved in the development of a tumor among those growth factors. 10 By interacting with VEGF receptor types 1–3, the VEGF family controls angiogenesis. 11 The VEGFR-2 binding site is hydrophobic, hence VEGFR-2 inhibitors showed a wide variety of chemical configurations.…”

Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation

“…The immunomodulatory effect of such compound was assessed against TNF-α and IL-6. It showed a significant decrease in TNF-α level [ 50 ], ( Figure 2 ).…”